Hospira Vinorelbine Tartrate 50 mg/5 mL Injection vial

País: Australia

Idioma: inglés

Fuente: Department of Health (Therapeutic Goods Administration)

Ingredientes activos:

vinorelbine tartrate, Quantity: 13.85 mg/mL

Disponible desde:

Hospira Australia Pty Ltd

Designación común internacional (DCI):

Vinorelbine tartrate

formulario farmacéutico:

Injection

Composición:

Excipient Ingredients: water for injections

Vía de administración:

Intravenous

Unidades en paquete:

1 X 5 mL

clase:

Medicine Listed (Export Only)

tipo de receta:

Not scheduled. Not considered by committee

indicaciones terapéuticas:

Vinorelbine is indicated as a single agent or in combination with cisplatin for the first-line treatment of ambulatory patients with unresectable, advanced nonsmall cell lung cancer (NSCLC). In patients with Stage IV NSCLC, Vinorelbine is indicated as a single agent or in combination with cisplatin. In Stage III NSCLC, Vinorelbine is indicated in combination with cisplatin.

Resumen del producto:

Visual Identification: A clear, colourless to pale yellow solution & free from visible particulates; Container Type: Vial; Container Life Time: 2 Years; Container Temperature: Store at 2 to 8 degrees Celsius

Estado de Autorización:

Licence status A

Fecha de autorización:

2008-05-21